Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

FOSTER CITY, Calif., Oct. 23, 2023 -- Apollomics Inc. , today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical...

Related Keywords

Madrid ,Spain ,United States ,China ,Beijing ,Kunpeng ,Guangdong ,Guo Liang Yu ,Sean Leous ,Peter Vozzo ,Nasdaq ,Pearl Biotechnology Ltd ,European Society Of Medical Oncology Congress ,Securities Exchange ,Apollomics Inc ,Avistone Biotechnology Ltd ,European Society ,Medical Oncology Congress ,Non Small Cell Lung Cancer ,Chief Executive Officer ,Apollomic China ,Avistone Biotechnology ,Beijing Pearl Biotechnology Ltd ,Securities Act ,Securities Exchange Act ,Annual Report ,Markets ,